In today’s briefing:
- Sunwels Co (9229) – Nursing Care Operator Offering and TOPIX Inclusion
- IHH Healthcare (IHH MK): Outstanding Performance in 1Q24; Looking for Business Expansion
- Inspire Medical Systems Inc.: Expansion in International Markets & 3 Factors Driving Our ‘Buy’ Rating! – Major Drivers
- Exelixis Inc.: Zanzalintinib Clinical Progression and Market Development Strategy! – Major Drivers
- CVRx: Enhancing Cardiac Care Through Neuromodulation
- Intra-Cellular Therapies Inc.: How They Are Expanding Market Opportunities for CAPLYTA! – Major Drivers
- Masimo Corporation: Proposed Separation of Consumer Health Division & Major Developments
- The Ensign Group Inc.: Is Their Approach Of Strategic Expansion Through Acquisitions Working?
- Encompass Health Corporation: A Tale Of Revenue Growth and Market Expansion!
- Option Care Health Inc.: Market Expansion Through Strategic Therapies & AI! – Major Drivers
Sunwels Co (9229) – Nursing Care Operator Offering and TOPIX Inclusion
- On 2 July 2024, nursing care operator SUNWELS Co (9229 JP) announced a sale of Treasury shares and newly-issued shares, and with it, a move to TSE Prime (therefore TOPIX)
- The stock, of course, popped. The stock starts with VERY low float because the CEO and his company own 64% of shares out ex-treasury.
- The offering is much larger than the TOPIX inclusion, so this is really more about the growth story.
IHH Healthcare (IHH MK): Outstanding Performance in 1Q24; Looking for Business Expansion
- IHH Healthcare (IHH MK) reported highest ever quarterly revenue in 1Q24, with double-digit growth across key metrics. 1Q24 revenue increased 16%, while EBITDA grew at a faster pace of 19%.
- Favorable patient mix, which was inclined to more acute and complex patients and price adjustments to counter inflation drove the growth. 1Q24 EBITDA margin (22.9%) improved from year-ago quarter (22.3%).
- The company expects favorable tailwinds from secular trends in its core markets, which will underpin longer-term growth. IHH is on track to add ~4,000 beds (+33% capacity) by 2028.
Inspire Medical Systems Inc.: Expansion in International Markets & 3 Factors Driving Our ‘Buy’ Rating! – Major Drivers
- Inspired Medical Systems First Quarter 2024 performance showcases a robust growth trajectory alongside strategic market advancements and impending innovations.
- The company reported a notable increase in revenue, which reached $164 million, marking a 28% year-over-year growth.
- This uplift was primarily driven by enhanced penetration in existing markets and expansion into new territories, both domestically and internationally.
Exelixis Inc.: Zanzalintinib Clinical Progression and Market Development Strategy! – Major Drivers
- Exelixis reported its first quarter 2024 financial results, underlining continued progress in its business across several fronts.
- The company, known for its cabozantinib franchise, saw a modest growth in revenues, driven by sustained demand and expansion in the U.S. and global markets.
- Additionally, Exelixis advanced in its pipeline development and corporate developments, maintaining a robust focus on enhancing standard of cancer care and providing value to shareholders.
CVRx: Enhancing Cardiac Care Through Neuromodulation
- CVRx (CVRX US)’s Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target.
- Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.
- Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.
Intra-Cellular Therapies Inc.: How They Are Expanding Market Opportunities for CAPLYTA! – Major Drivers
- Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and clinical realms.
- The company reported a significant rise in total revenues, reaching $144.9 million with CAPLYTA net sales alone accounting for $144.8 million, reflecting a 53% growth year-over-year.
- This growth trajectory reaffirms the drug’s strong market acceptance and penetration within its approved indications for bipolar depression and schizophrenia.
Masimo Corporation: Proposed Separation of Consumer Health Division & Major Developments
- Masimo Corporation reported its first quarter 2024 results with both encouraging and modest aspects.
- The company achieved a consolidated revenue of $493 million with healthcare revenues at the high end of guidance at $340 million, representing a 2% decline compared to the previous year.
- This figure aligns with the challenging comparison against the prior year’s performance, particularly in a period following intense COVID-19 related activities.
The Ensign Group Inc.: Is Their Approach Of Strategic Expansion Through Acquisitions Working?
- The Ensign Group, Inc. reported notable financial results for the first quarter of fiscal year 2024, demonstrating continued strong performance and growth across its portfolio.
- The company is well-known for operating a diverse array of subsidiaries that offer an array of health care services, including skilled nursing, rehabilitative care, and more, utilizing a unique business model of decentralized operations.
- On a positive note, the Ensign Group reported an increase in both revenue and earnings, attributing success to strong same-store occupancy and skilled mix.
Encompass Health Corporation: A Tale Of Revenue Growth and Market Expansion!
- Encompass Health Corporation released its First Quarter 2024 earnings, showing a robust financial performance characterized by a 13.4% increase in revenue and a 19.2% rise in adjusted EBITDA.
- This performance has prompted the company to raise its full-year 2024 guidance, signaling a positive outlook based on the quarter’s results.
- The growth was primarily driven by an increase in total discharges and strategic initiatives, including the expansion into de novo hospitals and addition of inpatient beds.
Option Care Health Inc.: Market Expansion Through Strategic Therapies & AI! – Major Drivers
- This is our first report on Option Care Health.
- The company reported a decent set of Fourth Quarter 2023 Earnings.
- They attribute a significant part of their growth to their commitment to offering innovative services aiming to improve patient outcomes and reduce costs.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
